Kinetics and mechanisms in lipopolysaccharide-induced neuroinflammation: a framework for phytochemicals screening

Abstract Neuroinflammation is an innate immune response of the central nervous system in which microglia, astrocytes and neuronal stress pathways regulate the production of cytokines, inflammatory enzymes and redox mediators. Among experimental paradigms, lipopolysaccharide (LPS) provides a stimulus for probing inflammatory signalling and for evaluation of phytochemicals. However, heterogeneity in LPS provenance, chemotype, purification grade, dose, route, exposure duration and endpoint timing compromises cross-study comparability, mechanistic attribution and translational interpretation. This review synthesises evidence from in vitro and in vivo LPS-induced neuroinflammation models used for phytochemical screening and proposes a kinetics- and mechanism-informed framework for experimental design. In vitro, murine microglial systems predominate, particularly BV-2, N9 and primary microglia, with complementary use of astroglia, neuronal and human myeloid or microglia-like platforms. LPS concentrations range from 100 ng/mL to 1 µg/mL, with signalling activation occurring within minutes to hours and inflammatory phenotypes typically assessed at 24–48 h. Frequently used pharmacodynamic readouts include tumour necrosis factor-α, interleukin-1β, interleukin-6, inducible nitric oxide synthase/nitric oxide, cyclooxygenase-2/prostaglandin E2, reactive oxygen species, glial activation markers and viability indices, combined with mechanistic interrogation of NF-κB, MAPK, PI3K–Akt, Nrf2–HO-1 and NLRP3-associated pathways. In vivo, repeated intraperitoneal LPS administration predominates in rodent models, whereas intracerebroventricular and zebrafish models provide complementary spatial and kinetic insights. Overall, LPS challenge should be interpreted as a controlled inflammatory trigger rather than a disease-equivalent surrogate. Rigorous LPS reporting, closer alignment of endpoints with inflammatory kinetics, and multi-endpoint validation across models should strengthen mechanistic inference and support translational evaluation of phytochemical leads. Graphical abstract Kinetics and mechanism informed framework for phytochemical screening in LPS-induced neuroinflammation. Created in BioRender. Zhou, P. (2026) https://BioRender.com/8jznpa5.

Authors

Publication Details

Journal
Molecular Biology Reports
Published
2026-10-08
DOI
https://doi.org/10.1007/s11033-026-12817-4
Primary Topic
Neuroinflammation and Neurodegeneration Mechanisms
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Kinetics and mechanisms in lipopolysaccharide-induced neuroinflammation: a framework for phytochemicals screening

Xian Zhou, Dennis H-T Chang, Muhammad Mazhar Munir
Molecular Biology Reports
Neuroinflammation and Neurodegeneration Mechanisms
article

Kinetics and mechanisms in lipopolysaccharide-induced neuroinflammation: a framework for phytochemicals screening

Xian Zhou, Dennis H-T Chang, Muhammad Mazhar Munir
article en

Abstract

Abstract Neuroinflammation is an innate immune response of the central nervous system in which microglia, astrocytes and neuronal stress pathways regulate the production of cytokines, inflammatory enzymes and redox mediators. Among experimental paradigms, lipopolysaccharide (LPS) provides a stimulus for probing inflammatory signalling and for evaluation of phytochemicals. However, heterogeneity in LPS provenance, chemotype, purification grade, dose, route, exposure duration and endpoint timing compromises cross-study comparability, mechanistic attribution and translational interpretation. This review synthesises evidence from in vitro and in vivo LPS-induced neuroinflammation models used for phytochemical screening and proposes a kinetics- and mechanism-informed framework for experimental design. In vitro, murine microglial systems predominate, particularly BV-2, N9 and primary microglia, with complementary use of astroglia, neuronal and human myeloid or microglia-like platforms. LPS concentrations range from 100 ng/mL to 1 µg/mL, with signalling activation occurring within minutes to hours and inflammatory phenotypes typically assessed at 24–48 h. Frequently used pharmacodynamic readouts include tumour necrosis factor-α, interleukin-1β, interleukin-6, inducible nitric oxide synthase/nitric oxide, cyclooxygenase-2/prostaglandin E2, reactive oxygen species, glial activation markers and viability indices, combined with mechanistic interrogation of NF-κB, MAPK, PI3K–Akt, Nrf2–HO-1 and NLRP3-associated pathways. In vivo, repeated intraperitoneal LPS administration predominates in rodent models, whereas intracerebroventricular and zebrafish models provide complementary spatial and kinetic insights. Overall, LPS challenge should be interpreted as a controlled inflammatory trigger rather than a disease-equivalent surrogate. Rigorous LPS reporting, closer alignment of endpoints with inflammatory kinetics, and multi-endpoint validation across models should strengthen mechanistic inference and support translational evaluation of phytochemical leads. Graphical abstract Kinetics and mechanism informed framework for phytochemical screening in LPS-induced neuroinflammation. Created in BioRender. Zhou, P. (2026) https://BioRender.com/8jznpa5.

Molecular Biology ReportsVol. 53(1)
Openalex Percentile: Top 17%
Neuroinflammation and Neurodegeneration Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.